RxDoctor Payments Data

Ramon Lloret, MD

Interventional Cardiology · Miami, FLNPI 1760497507

Payments from drug & device makers

$214,168in general payments, 2019–2025

Across 380 payments — averaging $563.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$104K
  • Merck$77K
  • Novartis$19K
  • Boston Scientific$4K
  • Medtronic$3K
  • ZOLL Circulation Inc$3K
  • plus $4K from 35 others

What the payments were for

  • Consulting fees$2,5008%
  • Speaking & faculty fees$15,01547%
  • Travel & lodging$1,8546%
  • Food & beverage$12,27239%
  • Education$350%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$214,168 in reported general payments places this provider in the 85th percentile of 623 interventional cardiology providers in Florida.

See all interventional cardiology providers in Florida

Medicare billing

Part B allowed, 2024
$145,202
Medicare patients
840
Services billed
2,303

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban495$603,044
EntrestoSacubitril/Valsartan252$354,411
Repatha SureclickEvolocumab154$170,681
FarxigaDapagliflozin Propanediol81$88,404
VascepaIcosapent Ethyl102$68,889
XareltoRivaroxaban66$63,281
MultaqDronedarone Hcl32$44,275
BrilintaTicagrelor37$34,906
JardianceEmpagliflozin24$24,286
Praluent PenAlirocumab16$17,806
Ezetimibe734$15,918
Rosuvastatin Calcium1,118$15,197
CorlanorIvabradine Hcl11$11,771
OzempicSemaglutide11$10,090
Metoprolol Succinate709$9,272

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$159$603,044495 claims
NovartisEntresto$19,364$354,411252 claims
AstraZenecaFarxiga, Brilinta$104,493$123,310118 claims
Johnson & JohnsonXarelto$232$63,28166 claims
Sanofi-aventis U.S. LLCMultaq$153$44,27532 claims
Boehringer IngelheimJardiance$80$24,28624 claims
AmgenCorlanor$269$11,77111 claims
Novo NordiskOzempic$274$10,09011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 623 interventional cardiology providers in Florida.

Other interventional cardiology in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →